Summary of Clinical Use

Otilimab was advanced into clinical trials, initially in rheumatoid arthritis and multiple sclerosis [3]. SARS-CoV-2 and COVID-19: Otilimab was investigated in a Phase 2 RCT, in patients with severe COVID-19, as a mechanism to reduce severe inflammatory lung complications, improve lung function and potentially improve clinical outcomes. However, in October 2021, GSK announced that this trial had failed to detect efficacy, and that development of otilimab for COVID-19 was being discontinued.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT01023256	Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis	Phase 1/Phase 2 Interventional	MorphoSys AG		1
NCT01517282	Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis	Phase 1/Phase 2 Interventional	MorphoSys AG		2
NCT03970837	Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)	Phase 3 Interventional	GlaxoSmithKline		2
NCT04333147	Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)	Phase 3 Interventional	GlaxoSmithKline
NCT02683785	A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis	Phase 2 Interventional	GlaxoSmithKline
NCT04376684	Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease	Phase 2 Interventional	GlaxoSmithKline